CAFFEIN - An EC funded Marie Curie Initial Training Network
In a trans-European network one biotech company and ten academic partners aim to identify functional CAF subpopulations and CAF effector mechanisms, and to develop therapeutic antibodies targeting CAFs as a novel approach in cancer therapy. The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013/ under REA grant agreement n° .
CAFFEIN consists of leading European research groups and a company with complementary knowledge in this area and a critical mass of expertise for providing an excellent training in CAF function and translational cancer research.
Participants in CAFFEIN
CAFFEIN consists of leading European research groups and companies with complementary knowledge in the area of cancer therapy.
The aim of the project
The focus of the research training is on cancer associated fibroblasts which plays an important role in promoting tumor growth, invasion, and metastasis.